Adlai Nortye Ltd. granted an exclusive license to Jiangsu Aosaikang Pharmaceutical (Ask Pharm) for AN‑9025, an oral pan‑RAS(ON) inhibitor designed to target a broad spectrum of activating RAS mutations. The licensing deal hands Ask Pharm rights to develop and commercialize AN‑9025 in the agreed territory and signals continued industry interest in small molecules that address historically intractable RAS oncogenes. AN‑9025’s broad RAS coverage is relevant across multiple tumor types. The transaction moves the asset toward regional development resources and highlights an ongoing strategy of out‑licensing promising small molecules to partners positioned for local clinical execution and regulatory navigation.